Page 7 - Natco Pharma

Natco Pharma gains on tentative nod from USFDA for cancer drug

The stock up 9% to Rs 523 after the company said that its marketing partner, Mylan Inc., has received a US regulator tentative nod Sorafenib, the generic version of Nexavar.

Natco Pharma gains on sale of non-core business in US

The board approved the sale of Save Mart Pharmacy Stores located in USA which is non-core business

US regulator looms over Natco prospects

Company says no impact on product pipeline but Street awaits more clarity

Natco Pharma slips on USFDA observations

The stock slipped 11% to Rs 417 on the BSE in early morning trade.

USFDA observations on 2 units not to impact products: Natco

Natco Pharma Ltd has already sent response and compliance report for these observations